Efficacy of nipocalimab in patients with moderate-to-severe ocular symptoms of generalized myasthenia gravis in the phase 3 Vivacity-MG3 study.

What was studied

This was a post hoc look at the Vivacity-MG3 trial, a late-stage trial. The trial tested nipocalimab versus placebo, plus usual care, in generalised myasthenia gravis. This analysis focused on people with moderate-to-severe eye symptoms. They scored at least 2 points on an eye item of the MG-ADL scale. The team compared score changes through week 24.

What they found

Both groups had similar total scores at the start. At week 24, scores improved more with nipocalimab than with placebo. This held for the MG-ADL total score and for the eye score. More people on nipocalimab had an eye score gain of at least 2 points. Side effects were reported at similar rates in both groups.

What it means for patients

The authors say these results suggest nipocalimab may give lasting disease control. They say it may reduce eye symptoms and improve daily activities versus placebo. They call the results hypothesis-generating.

Why it is not certain yet

This was a post hoc analysis, done after the main trial. Only some trial patients had moderate-to-severe eye symptoms. The abstract does not give long-term safety results. The authors call the results hypothesis-generating.

Source

Efficacy of nipocalimab in patients with moderate-to-severe ocular symptoms of generalized myasthenia gravis in the phase 3 Vivacity-MG3 study.

We restate facts from the source record in our own words. The original wording belongs to its publisher.